Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

HAYWARD, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today reported financial results for the quarter and nine months ended September 30, 2007.

Net loss for the quarter and nine months ended September 30, 2007 were $11.1 million and $19.2 million, or $0.26 per share and $0.46 per share, compared to a net loss of $7.5 million and $24.9 million, or $0.22 and $0.76 per share, in the same periods last year.

Revenues were $1.9 million and $17.1 million for the quarter and nine months ended September 30, 2007, compared to $2.2 million and $7.8 million in the same periods in 2006. Revenues for the quarter were for development activities under the Roche-Kosan global development and commercialization agreement for epothilones.

Total operating expenses were $14.2 million and $39.4 million for the quarter and nine months ended September 30, 2007, including non-cash stock- based compensation expense of $0.7 million and $2.5 million, respectively, compared to $10.3 million and $34.1 million for the same periods last year. Research and development expenses were $12.3 million and $33.4 million for the quarter and nine months ended September 30, 2007, compared to $8.7 million and $28.4 million in the same periods in 2006. The increase for the quarter compared to the same period in the prior year was primarily due to costs associated with initiating the TIME registration program in multiple myeloma and investment in Kosan's epothilone program, including KOS-1584 process development which was funded by Roche, and development of the next generation epothilone, KOS-1803. General and administrative expenses were $1.9 million and $6.1 million for the quarter and nine months ended
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... (PRWEB) June 03, 2015 The ... a new world record by scaling CD-adapco’s flagship ... Blue Waters supercomputer. , STAR-CCM+ is a ... industries to stimulate innovation and lower product development ... and Blue Waters manufacturer Cray to push the ...
(Date:6/3/2015)... Global Stem Cells Group and ... to conduct Romania’s first ever stem cells harvesting and ... Miami-based Stem Cell Training, Inc., Cosmetic Surgeon Morad ... Marrow Stem Cell Training Course for medical professionals in ... practicing in Bucharest and Tel Aviv, Israel, and a ...
(Date:6/3/2015)... Intelligent Implant Systems, LLC is pleased ... 9,044,273, underpinning the Revolution™ Spinal System. Revolution™ is ... procedure by eliminating complicated reusable non-sterile instrument trays ... tray. The implants, designed specifically for this new ... Intelligent Implant Systems has additional patents on this ...
(Date:6/2/2015)... -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer ... agreement whereby the institutional investors will have the option ... Company up to $4.93M in near term funding, pending ... the restructured terms and subject to certain market conditions, ... result in a larger influx of capital to fund ...
Breaking Biology Technology:NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... and MONTREAL, March 11 /PRNewswire/ - GreenField Ethanol,Canada,s ... and,catalysis technology company, have signed a Binding Term ... a commercial scale., "We are excited to ... reality in Canada," said Bob Gallant, President and ...
... March 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... joined PBI,s senior executive management team as Vice ... twenty years of experience in,sales and sales management ... Potter will oversee PBI,s seven US-based, regional sales ...
... FRANCISCO, Calif., March 11 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the discovery, development and commercialization of,novel small-molecule therapeutics, ... year ended December 31, 2007., Total revenue ... million, with a,net loss of $8.8 million. Total ...
Cached Biology Technology:GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality 2GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10
(Date:5/26/2015)... , May 26, 2015 ... the addition of the "Saudi Arabia Biometric ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... is projected to grow at over ... growth is attributed to the surging demand for ...
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... - University of Toronto research has found that purple loosestrife ... light and nutrients and can degrade habitats for wildlife ... it has spread to northern Ontario. This has allowed ... with a more than 30-fold increase in seed production. ...
... of zebrafish offers an explanation as to why some ... that male zebrafish regenerate their pectoral fins poorly, as ... October 14 issue of the Cell Press journal ... regenerative deficiency: structures that are used to improve reproductive ...
... For a long time, it was thought impossible to ... team has achieved this elusive goal. Scientists Joana Meyer, ... by Prof. Bruce McDonald, and Laurent Cartier of the ... Krzemnicki, succeeded for the first time in extracting trace ...
Cached Biology News:Natural selection enables purple loosestrife to invade northern Ontario 2Sex over survival: Reproductive trait in fish impedes tissue regeneration 2A bad break for fake pearls 2
...
... Immunogen: Synthetic Peptide: M(1) E F ... G P P T M D L E(19) ... mouse cells.,PA1-072 has been successfully used in Western ... detects an ~86 kDa protein representing Mint3 from ...
... The PolarScreen Androgen Receptor (AR) Competitor Assay ... for studying and screening potential AR ligands ... rat AR ligand binding domain protein tagged ... a novel, selective fluorescent androgen ligand (Fluormone ...
... offers bespoke, cost-effective solutions for complex protein processing and ... and experience to help you develop a solution to ... , ... transfer all methodology to your ...
Biology Products: